Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07699471 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Investigate Canvuparatide Compared With Placebo in Adult Patients With Hypoparathyroidism

StatusRecruiting
PhasePhase 3
Started2026-08-26
View on ClinicalTrials.gov ↗

Amendment history

  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
2026-09-22
Start dateestimated 2026-08→confirmed 2026-08-26
Eligibility criteria+30 characters
Key Inclusion Criteria: 1. Is an adult ≥18 years of age. 2. Has a documented diagnosis of post-surgical, chronic HypoPT [...] utoimmune HypoPT for at least 12 months prior to screening. 3. Intact PTH level below the median value of the normal range 4. Minimum requirement for a dose of calcitriol ≥0.5 μg/day, or [...] m should be stable for at least 3 weeks prior to screening. 5. Two (2) consecutive measurements of albumin-adjusted serum c [...] to 9.4 mg/dL (1.95 to 2.35 mmol/L). Key Exclusion Criteria: 1. Has a known history of pseudohypoparathyroidism 2. Clinically significant abnormal hematology, clinical chem [...] [...]
2026-08-27
Study Status, Contacts/Locations v3
Trial sites expanded: 2 → 10 locations
2026-08-25
Study Status, Contacts/Locations, References v2
Study sites2→10
2026-07-07
Original filing
The purpose of this study is to investigate the efficacy and safety of canvuparatide administered as a once-weekly (QW) treatment to adult study participants with hypoparathyroidism (HypoPT).
Trial Details
NCT Number NCT07699471
Lead Sponsor MBX Biosciences
Conditions Hypoparathyroidism
Enrollment 160 participants
Start Date 2026-08-26
Primary Completion 2028-01 (estimated)
Study Completion 2029-08 (estimated)
Updated on ClinicalTrials.gov 2026-09-24